子宫内膜异位症
医学
雌激素
盆腔疼痛
选择性雌激素受体调节剂
内科学
子宫内膜
激素
敌手
雌激素受体
生物信息学
内分泌学
药理学
受体
癌症研究
子宫
松弛素
腹膜腔
子宫腺肌病
激素疗法
治疗方法
炎症
异位表达
作者
Yaping Xing,Fanhui Zhang,Mengdan Zhao,Hanbo Zhang,Hong Yuan,Tingting Meng
标识
DOI:10.1021/acsabm.6c00680
摘要
Endometriosis (EMs) is a common gynecological disorder in women of reproductive age, often presenting with pelvic pain and infertility. Its progression is closely linked to estrogen levels. While hormonal therapies are effective, long-term use can disrupt systemic hormone balance. To address this, we developed M1 macrophage membrane-derived nanovesicles (M1NVs) that leverage the natural CCL2-CCR2 targeting axis to selectively deliver drugs to ectopic endometrial lesions. The estrogen receptor antagonist bazedoxifene (BAZ) was encapsulated into M1NVs, enabling targeted delivery to ectopic tissue following systemic administration. This approach locally antagonizes estrogen signaling, resulting in effective attenuation of inflammatory infiltration, suppression of angiogenesis, and reduction of fibrosis, thereby inhibiting the growth of ectopic endometrial tissue. Importantly, it did not adversely affect ovarian or uterine structure and function. This strategy offers a targeted and efficient alternative for the treatment of endometriosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI